Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America.

Trial Profile

Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs CYD TDV (Primary)
  • Indications Dengue
  • Focus Registrational; Therapeutic Use
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 13 Jun 2018 Results of post-hoc analysis assessing effect of dengue serostatus on vaccine safety and efficacy by using data from four trials including this trial published in the New England Journal of Medicine.
    • 30 Dec 2017 Results of post hoc pooled analysis from two phase 3 trial (NCT01373281 and NCT01374516) assessing the impact of dengue vaccination on the serological diagnosis of dengue in larger and more diverse epidemiological settings, were published in the Clinical Infectious Diseases.
    • 01 Dec 2017 Results of utilization of medical and nonmedical resources and cost of dengue by using data from two studies including this study published in the American Journal of Tropical Medicine and Hygiene.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top